Page 83 - Demo

Vitamin B12 and folic acid in advanced oesophageal and gastric cancer814References1. Pohl H, Sirovich B, Welch HG (2010) Esophageal adenocarcinoma incidence: are we reaching the peak? Cancer Epidemiol Biomarkers Prev 19 (6):1468-1470. doi:10.1158/1055-9965.EPI-10-00122. Conroy T, Marchal F, Blazeby JM (2006) Quality of life in patients with oesophageal and gastric cancer: an overview. Oncology 70 (6):391-402. doi:10.1159/0000990343. Lagergren J, Smyth E, Cunningham D, Lagergren P (2017) Oesophageal cancer. Lancet. doi:10.1016/S0140-6736(17)31462-94. Homs MY, v d Gaast A, Siersema PD, Steyerberg EW, Kuipers EJ (2006) Chemotherapy for metastatic carcinoma of the esophagus and gastro-esophageal junction. Cochrane Database Syst Rev (4):CD004063. doi:10.1002/14651858.CD004063.pub25. Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ, Van Groeningen CJ (2004) Phase II study of cisplatin preceding gemcitabine in patients with advanced oesophageal cancer. Ann Oncol 15 (2):230-2356. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (14):2636-2644. doi:10.1200/JCO.2003.11.1367. Symanowski JT, Rusthoven J, Nguyen B (2003) Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed plus cisplatin vs. cisplatin in malignant pleural mesothelioma Proc Am Soc Clin Oncol 22:647a8. Lu Y, Han J, Scanlon KJ (1988) Biochemical and molecular properties of cisplatin-resistant A2780 cells grown in folinic acid. J Biol Chem 263 (10):4891-48949. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T (1991) Cisplatin resistance in human cancers. Pharmacol Ther 52 (3):385-40610. Scanlon KJ, Kashani-Sabet M, Miyachi H, Sowers LC, Rossi J (1989) Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. Anticancer Res 9 (5):1301-131211. Jansen G, Peters GJ (2015) Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer. Pteridines 26 (2):41%u201353. doi:10.1515/pterid-2015-000512. Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, Colnaghi MI, Menard S (1997) Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br J Cancer 76 (1):77-8213. Backus HH, Pinedo HM, Wouters D, Padron JM, Molders N, van Der Wilt CL, van Groeningen CJ, Jansen G, Peters GJ (2000) Folate depletion increases sensitivity of solid tumor cell lines to 5-fluorouracil and antifolates. Int J Cancer 87 (6):771-77814. Lemos C, Kathmann I, Giovannetti E, Dekker H, Scheffer GL, Calhau C, Jansen G, Peters GJ (2008) Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells. Int J Cancer 123 (7):1712-1720. doi:10.1002/ijc.2367715. Keepers YP, Pizao PE, Peters GJ, van Ark-Otte J, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27 (7):897-90016. van Moorsel CJ, Kroep JR, Pinedo HM, Veerman G, Voorn DA, Postmus PE, Vermorken JB, van Groeningen CJ, van der Vijgh WJ, Peters GJ (1999) Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors. Ann Oncol 10 (4):441-44817. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (3):205-21618. Ciccolini J, Serdjebi C, Peters GJ, Giovannetti E (2016) Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemotherapy and Pharmacology 78 (1):1-12. doi:10.1007/s00280-016-3003-0